Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have been assigned a consensus broker rating score of 1.50 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.
Brokers have set a one year consensus price target of $15.50 for the company and are forecasting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Leap Therapeutics an industry rank of 194 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Wednesday, January 3rd.
Leap Therapeutics (NASDAQ LPTX) traded up $0.51 during midday trading on Thursday, hitting $7.25. The company had a trading volume of 210,413 shares, compared to its average volume of 67,457. Leap Therapeutics has a 12 month low of $4.90 and a 12 month high of $9.44. The firm has a market cap of $79.81, a P/E ratio of -2.07 and a beta of 1.10.
A hedge fund recently bought a new stake in Leap Therapeutics stock. Sabby Management LLC bought a new position in shares of Leap Therapeutics Inc (NASDAQ:LPTX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned about 0.72% of Leap Therapeutics as of its most recent SEC filing. 3.25% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/03/15/brokerages-set-15-50-price-target-for-leap-therapeutics-inc-nasdaqlptx.html.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.